Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals Inc, 13586 [2021-04809]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
13586
Federal Register / Vol. 86, No. 44 / Tuesday, March 9, 2021 / Notices
calendarpad/calendar.html. Interested
parties should check the Commission’s
website periodically for updates.
Requests to appear at the hearing should
be filed in writing with the Secretary to
the Commission on or before May 6,
2021. A nonparty who has testimony
that may aid the Commission’s
deliberations may request permission to
present a short statement at the hearing.
All parties and nonparties desiring to
appear at the hearing and make oral
presentations should attend a
prehearing conference to be held at 9:30
a.m. on May 7, 2021, if deemed
necessary. Oral testimony and written
materials to be submitted at the public
hearing are governed by sections
201.6(b)(2), 201.13(f), and 207.24 of the
Commission’s rules. Parties must submit
any request to present a portion of their
hearing testimony in camera no later
than 7 business days prior to the date of
the hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
filing is May 4, 2021. Parties may also
file written testimony in connection
with their presentation at the hearing, as
provided in § 207.24 of the
Commission’s rules, and posthearing
briefs, which must conform with the
provisions of section 207.25 of the
Commission’s rules. The deadline for
filing posthearing briefs is May 17,
2021. In addition, any person who has
not entered an appearance as a party to
the investigations may submit a written
statement of information pertinent to
the subject of the investigations,
including statements of support or
opposition to the petition, on or before
May 17, 2021. On June 4, 2021, the
Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before June 8, 2021, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
VerDate Sep<11>2014
17:03 Mar 08, 2021
Jkt 253001
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigations must be served on all
other parties to the investigations (as
identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to § 207.21 of the Commission’s
rules.
In
accordance with 21 CFR 1301.33(a), this
is notice that on February 2, 2021,
Patheon Pharmaceuticals Inc, 2110 East
Galbraith Road, Cincinnati, Ohio
45237–1625, applied to be registered as
a bulk manufacturer of the following
basic class of controlled substance:
SUPPLEMENTARY INFORMATION:
Controlled substance
Gamma Hydroxybutyric
Acid.
Drug
code
Schedule
2010
I
The company plans to manufacture
the above-listed controlled substance as
Active Pharmaceutical Ingredient (API)
that will be further synthesized into
Food and Drug Administrationapproved dosage forms. No other
activities for this drug code are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–04809 Filed 3–8–21; 8:45 am]
By order of the Commission.
Issued: March 4, 2021.
Lisa Barton,
Secretary to the Commission.
BILLING CODE 4410–09–P
[FR Doc. 2021–04860 Filed 3–8–21; 8:45 am]
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
BILLING CODE 7020–02–P
[Docket No. DEA–804]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: Patheon
Pharmaceuticals Inc
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Patheon Pharmaceuticals Inc
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 10, 2021. Such persons
may also file a written request for a
hearing on the application on or before
May 10, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
Frm 00068
Fmt 4703
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
[Docket No. DEA–802]
PO 00000
Bulk Manufacturer of Controlled
Substances Application: Stepan
Company
Sfmt 4703
Stepan Company has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 10, 2021. Such persons
may also file a written request for a
hearing on the application on or before
May 10, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on February 8, 2021,
Stepan Company, 100 West Hunter
Avenue, Maywood, New Jersey 07607–
SUPPLEMENTARY INFORMATION:
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 86, Number 44 (Tuesday, March 9, 2021)]
[Notices]
[Page 13586]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04809]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-802]
Bulk Manufacturer of Controlled Substances Application: Patheon
Pharmaceuticals Inc
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Patheon Pharmaceuticals Inc has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before May 10, 2021.
Such persons may also file a written request for a hearing on the
application on or before May 10, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on February 2, 2021, Patheon Pharmaceuticals Inc, 2110
East Galbraith Road, Cincinnati, Ohio 45237-1625, applied to be
registered as a bulk manufacturer of the following basic class of
controlled substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid............... 2010 I
------------------------------------------------------------------------
The company plans to manufacture the above-listed controlled
substance as Active Pharmaceutical Ingredient (API) that will be
further synthesized into Food and Drug Administration-approved dosage
forms. No other activities for this drug code are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-04809 Filed 3-8-21; 8:45 am]
BILLING CODE 4410-09-P
